SDS-Page
(Hydrolysis of recombinant aggrecan interglobular domain with isolated ADAMTS4. Recombinant aggrecan-IGD1 at a concentration of 10uM in 50mM Tris-HCl, pH7.5, 150mM NaCl, 5mM CaCl2 was incubated with out and with 0.1uM truncated ADAMTS-4 for various time intervals. Aliquots with 1.5ug aggrecan-IGD1 were then analyzed by SDS-PAGE. Lane 1: Aggrecan-IGD1 incubated with out ADAMTS4, Lanes 2-6: Digestion mixtures of aggrecan-IGD1 with ADAMTS4 after 0, 0.5, 1, 2, and 5 hours incubation.)
Aggrecan, Interglobular Domain Recombinant Protein | ACAN recombinant protein
Aggrecan, Recombinant, Interglobular Domain (Aggrecan IgD1, Proteoglycan, PG, AGC 1, Aggrecan 1, Antigen identified by monoclonal A0122, Cartilage specific proteoglycan core protein, Chondroitin sulfate proteoglycan core protein 1, CSPCP, CSPG1, CSPGCP, L
Recombinant aggrecan interglobular domain appears as a major band at about 21kD in SDS-PAGE, representing 90% of total protein in the preparation.
Recombinant aggrecan interglobular domain appears as a major band at about 21kD in SDS-PAGE, representing 90% of total protein in the preparation.
SDS-Page
(Hydrolysis of recombinant aggrecan interglobular domain with isolated ADAMTS4. Recombinant aggrecan-IGD1 at a concentration of 10uM in 50mM Tris-HCl, pH7.5, 150mM NaCl, 5mM CaCl2 was incubated with out and with 0.1uM truncated ADAMTS-4 for various time intervals. Aliquots with 1.5ug aggrecan-IGD1 were then analyzed by SDS-PAGE. Lane 1: Aggrecan-IGD1 incubated with out ADAMTS4, Lanes 2-6: Digestion mixtures of aggrecan-IGD1 with ADAMTS4 after 0, 0.5, 1, 2, and 5 hours incubation.)
SDS-Page
(Hydrolysis of recombinant aggrecan interglobular domain with isolated ADAMTS4. Recombinant aggrecan-IGD1 at a concentration of 10uM in 50mM Tris-HCl, pH7.5, 150mM NaCl, 5mM CaCl2 was incubated with out and with 0.1uM truncated ADAMTS-4 for various time intervals. Aliquots with 1.5ug aggrecan-IGD1 were then analyzed by SDS-PAGE. Lane 1: Aggrecan-IGD1 incubated with out ADAMTS4, Lanes 2-6: Digestion mixtures of aggrecan-IGD1 with ADAMTS4 after 0, 0.5, 1, 2, and 5 hours incubation.)
To measure aggrecanase activity, an artificial recombinant protein composed of aggrecan interglobular domain with flanking DYKDDDDK-sequence and human immunoglobulin G1 constant region was first used by Hughes et al. (8).
NCBI and Uniprot Product Information
NCBI Description
This gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration. Multiple alternatively spliced transcript variants that encode different protein isoforms have been observed in this gene. [provided by RefSeq, Jul 2008]
Uniprot Description
ACAN: This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region. Defects in ACAN are the cause of spondyloepiphyseal dysplasia type Kimberley (SEDK). Spondyloepiphyseal dysplasias are a heterogeneous group of congenital chondrodysplasias that specifically affect epiphyses and vertebrae. The autosomal dominant SEDK is associated with premature degenerative arthropathy. Defects in ACAN are the cause of spondyloepimetaphyseal dysplasia aggrecan type (SEMD-ACAN). A bone disease characterized by severe short stature, macrocephaly, severe midface hypoplasia, short neck, barrel chest and brachydactyly. The radiological findings comprise long bones with generalized irregular epiphyses with widened metaphyses, especially at the knees, platyspondyly, and multiple cervical-vertebral clefts. Defects in ACAN are the cause of osteochondritis dissecans short stature and early-onset osteoarthritis (OD). It is a type of osteochondritis defined as a separation of cartilage and subchondral bone from the surrounding tissue, primarily affecting the knee, ankle and elbow joints. It is clinically characterized by multiple osteochondritic lesions in knees and/or hips and/or elbows, disproportionate short stature and early-onset osteoarthritis. Belongs to the aggrecan/versican proteoglycan family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Extracellular matrix; Cell adhesion; Secreted, signal peptide; Secreted
Chromosomal Location of Human Ortholog: 15q26.1
Cellular Component: extracellular matrix; lysosomal lumen; proteinaceous extracellular matrix; Golgi lumen; extracellular region
Molecular Function: protein binding; extracellular matrix structural constituent; metal ion binding; hyaluronic acid binding; carbohydrate binding
Biological Process: keratan sulfate metabolic process; extracellular matrix disassembly; extracellular matrix organization and biogenesis; glycosaminoglycan metabolic process; carbohydrate metabolic process; keratan sulfate biosynthetic process; pathogenesis; keratan sulfate catabolic process; proteolysis; cell adhesion; skeletal development
Disease: Spondyloepiphyseal Dysplasia, Kimberley Type; Osteochondritis Dissecans, Short Stature, And Early-onset Osteoarthritis; Spondyloepimetaphyseal Dysplasia, Aggrecan Type
Research Articles on ACAN
Similar Products
Product Notes
The ACAN acan (Catalog #AAA637420) is a Recombinant Protein and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's Aggrecan, Interglobular Domain can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA). Aggrecan interglobular domain is used as substrate for aggrecanases and matrix metalloproteinases. For proteinase activity measurements, the protein is incubated with proteinase for various time intervals. Thereafter, aliquots of the incubation mixture are analyzed by SDS-PAGE or by ELISA. Upon cleavage with aggrecanases the apparent Mr of aggrecan interlobular domain in SDS-PAGE is reduced from 21kD to ~13kD. Quantitative measurement of aggrecanase cleavage requires a neoepitope antibody with specificity for the N-terminus ARGSVILT.. appearing upon hydrolysis. The fragment with the newly formed N-terminus is fixed by the neoepitope antibody to a microplate and quantified with an anti-His-tag antibody. In analogy, cleavage by matrix metalloproteinases can be measured with antibodies to neoepitopes appearing upon action of these enzymes. Researchers should empirically determine the suitability of the ACAN acan for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Aggrecan, Interglobular Domain, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
